methandriol and Leiomyoma

A double-blind between-patient trial was carried out in 200 women suffering from dysfunctional menorrhagia (142) or from menorrhagia associated with uterine fibromyomatosis (58) to assess and compare the effectiveness of a polypeptide preparation ('Lysometra') and methylandrostendiol in reducing hyperoestrogenism and clinical symptoms. Three 20-day courses of intramuscular injections of either 2.5 ml 'Lysometra' or 5 mg methylandrostendiol were given to matched pairs of patients, with an 8-day interval between. Results, as assessed by absolute and percentage changes in total urine oestrogen levels and by overall clinical response of patients, showed that 'Lysometra' produced a statistically significant greater effect than methylandrostendiol. The biological preparation was well tolerated and no unwanted side-effects were reported.

Topics: Androstenediols; Clinical Trials as Topic; Estrogens; Female; Humans; Injections, Intramuscular; Leiomyoma; Menorrhagia; Methandriol; Peptides; Uterine Neoplasms